1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
02/26/2024 | DGX | Buy Now | Quest Diagnostics | $128.14 | 5.35% | Leerink Partners | Michael Cherny | → $135 | Initiates | → Market Perform | Get Alert |
02/07/2024 | DGX | Buy Now | Quest Diagnostics | $128.14 | 20.96% | Jefferies | Brian Tanquilut | $140 → $155 | Upgrade | Hold → Buy | Get Alert |
02/02/2024 | DGX | Buy Now | Quest Diagnostics | $128.14 | 13.16% | Truist Securities | David Macdonald | $150 → $145 | Maintains | Hold | Get Alert |
12/20/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 17.06% | Truist Securities | David Macdonald | $145 → $150 | Maintains | Hold | Get Alert |
12/12/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 24.86% | B of A Securities | Derik De Bruin | $140 → $160 | Upgrade | Neutral → Buy | Get Alert |
12/11/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 13.16% | Citigroup | Patrick Donnelly | $130 → $145 | Maintains | Neutral | Get Alert |
12/07/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 6.91% | UBS | Kevin Caliendo | $135 → $137 | Maintains | Neutral | Get Alert |
11/17/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 16.28% | JP Morgan | John Stansel | $148 → $149 | Maintains | Neutral | Get Alert |
11/06/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 9.26% | Piper Sandler | David Westenberg | $130 → $140 | Maintains | Neutral | Get Alert |
10/25/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 1.45% | Citigroup | Patrick Donnelly | $142 → $130 | Maintains | Neutral | Get Alert |
10/16/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 1.45% | Piper Sandler | David Westenberg | $145 → $130 | Maintains | Neutral | Get Alert |
08/03/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 13.16% | Morgan Stanley | Ricky Goldwasser | $145 → $145 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
06/29/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 13.16% | Piper Sandler | David Westenberg | → $145 | Initiates | → Neutral | Get Alert |
05/10/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 13.16% | Morgan Stanley | Ricky Goldwasser | $158 → $145 | Maintains | Equal-Weight | Get Alert |
05/02/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 15.5% | B of A Securities | Derik De Bruin | $166 → $148 | Downgrade | Buy → Neutral | Get Alert |
04/03/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 10.82% | Citigroup | Patrick Donnelly | $125 → $142 | Upgrade | Sell → Neutral | Get Alert |
03/17/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 24.86% | Truist Securities | David Macdonald | $170 → $160 | Maintains | Hold | Get Alert |
03/17/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 28.77% | Mizuho | Ann Hynes | → $165 | Reiterates | → Buy | Get Alert |
02/03/2023 | DGX | Buy Now | Quest Diagnostics | $128.14 | 9.26% | Wells Fargo | Timothy Daley | $135 → $140 | Maintains | Equal-Weight | Get Alert |
The latest price target for Quest Diagnostics (NYSE: DGX) was reported by Leerink Partners on February 26, 2024. The analyst firm set a price target for $135.00 expecting DGX to rise to within 12 months (a possible 5.35% upside). 16 analyst firms have reported ratings in the last year.
The latest analyst rating for Quest Diagnostics (NYSE: DGX) was provided by Leerink Partners, and Quest Diagnostics initiated their market perform rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on February 26, 2024 so you should expect the next rating to be made available sometime around February 26, 2025.
While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a initiated with a price target of $0.00 to $135.00. The current price Quest Diagnostics (DGX) is trading at is $128.14, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.